Standard BioTools Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Standard BioTools Inc. (LAB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 6.11 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2026-08-05
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2026-06-30 was 1.14M shares, a 39.90% increase year-over-year.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2026-03-31 was 4.97M shares, a 14.34% increase year-over-year.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-09-30 was 0.00 shares.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2025 was 5.16M shares, a 22.92% decline from fiscal 2024.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2024 was 6.70M shares, a 156.69% increase from fiscal 2023.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2023 was 2.61M shares, a 66.59% decline from fiscal 2022.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2022 was 7.81M shares, a 8389.13% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.14M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 6.11M shares 10-Q · filed 2026-08-05 | 6.11M shares derived: sum of 3 quarters · filed 2026-08-05 | 6.11M shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 4.97M shares 10-Q · filed 2026-05-06 | 4.97M shares derived: sum of 2 quarters · filed 2026-05-06 | 4.97M shares derived: sum of 3 quarters · filed 2026-05-06 | 5.79M shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-16 | 817.00K shares derived: sum of 3 quarters · filed 2026-03-16 | 5.16M shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 817.00K shares derived: sum of 2 quarters · filed 2025-11-04 | 5.16M shares 10-Q · filed 2025-11-04 | 11.85M shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 817.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | 5.16M shares 10-Q · filed 2025-08-15 | 11.85M shares derived: sum of 3 quarters · filed 2025-08-15 | 11.85M shares derived: sum of 4 quarters · filed 2025-08-15 |
| 2025-03-31 | 4.34M shares 10-Q · filed 2025-05-06 | 11.04M shares derived: sum of 2 quarters · filed 2025-05-06 | 11.04M shares derived: sum of 3 quarters · filed 2025-05-06 | 11.04M shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 6.69M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 6.69M shares derived: sum of 2 quarters · filed 2025-03-11 | 6.70M shares derived: sum of 3 quarters · filed 2025-03-11 | 6.70M shares 10-K · filed 2025-03-11 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 6.40K shares derived: sum of 2 quarters · filed 2024-11-06 | 6.70K shares 10-Q · filed 2024-11-06 | 56.70K shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 6.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 6.70K shares 10-Q · filed 2024-08-06 | 56.70K shares derived: sum of 3 quarters · filed 2024-08-06 | 656.70K shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 300.00 shares 10-Q · filed 2024-05-09 | 50.30K shares derived: sum of 2 quarters · filed 2024-05-09 | 650.30K shares derived: sum of 3 quarters · filed 2024-05-09 | 1.66M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 50.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | 650.00K shares derived: sum of 2 quarters · filed 2024-03-01 | 1.66M shares derived: sum of 3 quarters · filed 2024-03-01 | 2.61M shares 10-K · filed 2024-03-01 |
| 2023-09-30 | 600.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 1.61M shares derived: sum of 2 quarters · filed 2023-11-07 | 2.56M shares 10-Q · filed 2023-11-07 | 2.56M shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 1.01M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 1.96M shares 10-Q · filed 2023-08-08 | 1.96M shares derived: sum of 3 quarters · filed 2023-08-08 | 1.96M shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 947.00K shares 10-Q · filed 2023-05-09 | 947.00K shares derived: sum of 2 quarters · filed 2023-05-09 | 947.00K shares derived: sum of 3 quarters · filed 2023-05-09 | 8.76M shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | 0.00 shares derived: sum of 2 quarters · filed 2023-03-14 | 7.81M shares derived: sum of 3 quarters · filed 2023-03-14 | 7.81M shares 10-K · filed 2023-03-14 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 7.81M shares derived: sum of 2 quarters · filed 2022-11-09 | 7.81M shares 10-Q · filed 2022-11-09 | 7.81M shares derived: sum of 4 quarters · filed 2023-03-14 |
| 2022-06-30 | 7.81M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 7.81M shares 10-Q · filed 2022-08-09 | 7.81M shares derived: sum of 3 quarters · filed 2023-03-14 | 7.81M shares derived: sum of 4 quarters · filed 2023-03-14 |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-09 | -1.00K shares derived: sum of 2 quarters · filed 2023-03-14 | -1.00K shares derived: sum of 3 quarters · filed 2023-03-14 | 92.00K shares derived: sum of 4 quarters · filed 2023-03-14 |
| 2021-12-31 | -1.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -1.00K shares derived: sum of 2 quarters · filed 2023-03-14 | 92.00K shares derived: sum of 3 quarters · filed 2023-03-14 | 92.00K shares 10-K · filed 2023-03-14 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | 93.00K shares derived: sum of 2 quarters · filed 2021-11-09 | 93.00K shares 10-Q · filed 2021-11-09 | 105.00K shares derived: sum of 4 quarters · filed 2022-03-08 |
| 2021-06-30 | 93.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | 93.00K shares 10-Q · filed 2021-08-06 | 105.00K shares derived: sum of 3 quarters · filed 2022-03-08 | 105.00K shares derived: sum of 4 quarters · filed 2022-03-08 |
| 2021-03-31 | 0.00 shares 10-Q · filed 2021-05-07 | 12.00K shares derived: sum of 2 quarters · filed 2022-03-08 | 12.00K shares derived: sum of 3 quarters · filed 2022-03-08 | 117.00K shares derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-12-31 | 12.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | 12.00K shares derived: sum of 2 quarters · filed 2022-03-08 | 117.00K shares derived: sum of 3 quarters · filed 2022-03-08 | 117.00K shares 10-K · filed 2022-03-08 |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | 105.00K shares derived: sum of 2 quarters · filed 2020-11-09 | 105.00K shares 10-Q · filed 2020-11-09 | 105.00K shares derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-06-30 | 105.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | 105.00K shares 10-Q · filed 2020-08-07 | 105.00K shares derived: sum of 3 quarters · filed 2022-03-08 | 114.00K shares derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-03-31 | 0.00 shares 10-Q · filed 2020-05-11 | 0.00 shares derived: sum of 2 quarters · filed 2022-03-08 | 9.00K shares derived: sum of 3 quarters · filed 2022-03-08 | 50.00K shares derived: sum of 4 quarters · filed 2022-03-08 |
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | 9.00K shares derived: sum of 2 quarters · filed 2022-03-08 | 50.00K shares derived: sum of 3 quarters · filed 2022-03-08 | 50.00K shares 10-K · filed 2022-03-08 |
| 2019-09-30 | 9.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | 50.00K shares derived: sum of 2 quarters · filed 2019-11-08 | 50.00K shares 10-Q · filed 2019-11-08 | |
| 2019-06-30 | 41.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | 41.00K shares 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | 0.00 shares 10-Q · filed 2019-05-07 | |||
| 2018-12-31 | 758.00K shares 10-K · filed 2021-02-25 | |||
| 2017-12-31 | 1.36M shares 10-K · filed 2020-02-27 | |||
| 2016-12-31 | 978.00K shares 10-K · filed 2019-03-18 | |||
| 2015-12-31 | 514.00K shares 10-K · filed 2016-02-29 | |||
| 2014-12-31 | 457.00K shares 10-K · filed 2015-02-26 | |||
| 2013-12-31 | 1.27M shares 10-K · filed 2014-03-12 | |||
| 2012-12-31 | 1.12M shares 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |